WHWK — Whitehawk Therapeutics, Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1422142 ·
Last close
$3.08
Market Cap
$181.75M
52W High
$5.49
52W Low
$1.97
ADV30
376,317
Next earnings
2026-11-09
Whitehawk Therapeutics, Inc., a clinical-stage oncology therapeutics company that develops technologies to establish tumor biology for cancer treatments. It provides three next generation antibody drug conjugates (ADC) portfolio to treat cancer. The company was formerly known as Aadi Bioscience, Inc. and changed its name to Whitehawk Therapeutics, Inc. in August 2021. Whitehawk Therapeutics, Inc. was incorporated in 2007 and is headquartered in Morristown, New Jersey.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 0 -22,943,000 -21,209,000 173,686,000 68,973,000 10,529,000
Jun 2026 0 0 -18,109,000 -16,640,000 193,994,000 85,234,000 11,069,000
Mar 2026 0 0 -23,522,000 -22,194,000 127,231,000 34,790,000 11,056,000
Dec 2025 0 0 -24,887,000 -23,251,000 150,830,000 37,568,000 14,519,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-73,644,000
Investing CF
$23,015,000
Financing CF
$81,671,000
CapEx
$-552,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.09
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-413,293,000
Inventory
$0
Receivables
$0
ST Investments
$100,699,000
EBIT TTM
$-87,825,000
Pretax Income TTM
$-83,294,000
Interest Exp TTM
$0
Analysts
7

Yahoo Snapshot (yfinance, live)

Total Revenue
$0
EBITDA
$-89,458,000
Free Cash Flow
$-47,464,124
Enterprise Value
$11,113,485
Total Cash
$169,672,000
Total Debt
$218,000
Shares Out
59,008,982
Trailing EPS
$-1.10
Book Value
$2.77
ROE
-52.0%
ROA
-32.8%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 7,145,000 -114,400,000 -20,596,000 150,830,000 14,519,000 136,311,000 -97,433,000
Dec 2024 25,983,000 -64,820,000 -63,691,000 70,319,000 17,841,000 52,478,000 -59,550,000
Dec 2023 24,354,000 -71,933,000 -65,765,000 132,423,000 27,228,000 105,195,000 -59,663,000
Dec 2022 15,216,000 -58,957,000 -60,513,000 184,237,000 25,859,000 158,378,000 -49,640,000

TTM Snapshot

Revenues TTM
$0
NetIncome TTM
$-79,831,000
OpCashFlow TTM
—
Assets (Latest)
$193,994,000
Forward EPS
$-1.00

Max Pain — expiry 2027-01-15 (volume-derived — Yahoo OI feed degraded)

max pain strike: $2.50 · spot: $3.13 · call volume: 2 · put volume: 1
Expected Move to 2027-01-15: ±$4.45 (142.17%) — implied range $-1.32 – $7.58 · ATM straddle on $2.50 strike

Peers — same industry

TickerNameMarket CapLastDaily %
NATR NATURES SUNSHINE PRODUCTS INC $179.01M $10.33 —
RNAC Cartesian Therapeutics, Inc. $186.68M $6.12 —
ADCT ADC Therapeutics SA $189.89M $1.35 —
SLGL Sol-Gel Technologies Ltd. $172.97M $52.83 —
PYXS Pyxis Oncology, Inc. $172.24M $1.44 —

News headlines (Yahoo Finance, 1h cache)

Akari Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Continued Progress Toward Clinical Development of Differentiated ADC Payload Platform
2026-11-12 21:05 · Yahoo
Whitehawk Therapeutics Reports Third Quarter 2026 Financial Results and Recent Highlights
2026-11-09 13:00 · Yahoo
Whitehawk Therapeutics Presents Real-World Analyses Supporting PTK7 as a Durable ADC Target in EGFR Wild-Type Non-Small Cell Lung Cancer at WCLC 2026
2026-09-14 01:30 · Yahoo
What Makes Whitehawk Therapeutics, Inc. (WHWK) a Strong Momentum Stock: Buy Now?
2026-08-28 16:00 · Yahoo
Wall Street Analysts Predict a 47.64% Upside in Whitehawk Therapeutics, Inc. (WHWK): Here's What You Should Know
2026-08-26 13:55 · Yahoo
Akari Therapeutics Enters Strategic Research Collaboration with Whitehawk Therapeutics
2026-07-21 11:05 · Yahoo
Biocytogen and Whitehawk Therapeutics Enter Global Collaboration for Bispecific Antibody ADC Development
2026-07-07 12:00 · Yahoo
Whitehawk Therapeutics to Present at the Jefferies 2026 Global Healthcare Conference
2026-05-28 20:05 · Yahoo
Is Whitehawk Therapeutics (WHWK) One Of The Hot Biotech Stocks Under $5 To Buy?
2026-06-10 18:22 · Yahoo
Whitehawk Therapeutics Presents Real‑World Analysis Confirming SEZ6 as a Highly Expressed, Clinically Relevant Target for SCLC and Other Neuroendocrine Tumors at ASCO 2026
2026-05-30 18:30 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.